Merck predicts a healthy 2004

Merck is expecting a promising 2004, predicting a profit increase of about 7% on a per-share basis, despite problems with research and the expiration of foreign patents on Zocor, its top seller. The drug company is benefiting from higher sales of several major drugs, including Fosamax and Singulair, but analysts are concerned about the company's health in 2006, when Zocor loses U.S. patent protection.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ